{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:53:37Z","timestamp":1791327217435,"version":"4.3.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host immune status has been reported to influence the efficacy of various systemic therapies, but its clinical significance in patients treated with T-DXd is not yet fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers\u2014including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio\u2014were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan\u2013Meier methods and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16548-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:26:16Z","timestamp":1783909576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-7984","authenticated-orcid":false,"given":"Akihiro","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Inohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nakame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yokogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"16548_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66.","journal-title":"Nat Rev Dis Primers"},{"key":"16548_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369.","journal-title":"Lancet"},{"key":"16548_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"16548_CR4","doi-asserted-by":"publisher","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Pandiella A, Vargas-Castrill\u00f3n E, D\u00edaz-Rodr\u00edguez E, Iglesias-Hernang\u00f3mez T, Mart\u00ednez Cano C, et al. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. 2024;198:104355.","journal-title":"Crit Rev Oncol Hematol"},{"key":"16548_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"16548_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"16548_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401:1773\u201385.","journal-title":"Lancet"},{"key":"16548_CR8","doi-asserted-by":"publisher","first-page":"175883592311754","DOI":"10.1177\/17588359231175440","volume":"15","author":"C Yang","year":"2023","unstructured":"Yang C, Brezden-Masley C, Joy AA, Sehdev S, Modi S, Simmons C, et al. Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Ther Adv Med Oncol. 2023;15:17588359231175440.","journal-title":"Ther Adv Med Oncol"},{"key":"16548_CR9","doi-asserted-by":"publisher","first-page":"oyaf174","DOI":"10.1093\/oncolo\/oyaf174","volume":"30","author":"C Xue","year":"2025","unstructured":"Xue C, Liao Q, Huang R, Huang Y, Chen R, Yang Z, et al. Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study. Oncologist. 2025;30:oyaf174.","journal-title":"Oncologist"},{"key":"16548_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-018-4888-2","volume":"18","author":"K Araki","year":"2018","unstructured":"Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 2018;18:982.","journal-title":"BMC Cancer"},{"key":"16548_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clbc.2018.03.002","volume":"18","author":"Y Miyagawa","year":"2018","unstructured":"Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18:400\u20139.","journal-title":"Clin Breast Cancer"},{"key":"16548_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer. 2020;27:706\u201315.","journal-title":"Breast Cancer"},{"key":"16548_CR13","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.21873\/anticanres.15095","volume":"41","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T. Dynamic changes in absolute lymphocyte Counts During eribulin therapy are associated with survival benefit. Anticancer Res. 2021;41:3109\u201319.","journal-title":"Anticancer Res"},{"key":"16548_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/mco.2024.2713","volume":"20","author":"H Shimada","year":"2024","unstructured":"Shimada H, Fujimoto A, Matsuura K, Kohyama S, Nukui A, Ichinose Y, et al. Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood-based parameters and ratio. Mol Clin Oncol. 2024;20:15.","journal-title":"Mol Clin Oncol"},{"key":"16548_CR15","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.1038\/s41598-021-85948-2","volume":"11","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T, Notsu A. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Sci Rep. 2021;11:6328.","journal-title":"Sci Rep"},{"key":"16548_CR16","doi-asserted-by":"publisher","first-page":"9869","DOI":"10.1038\/s41598-024-60101-x","volume":"14","author":"S Nakamoto","year":"2024","unstructured":"Nakamoto S, Shien T, Iwamoto T, Kubo S, Yamamoto M, Yamashita T, et al. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4\/6 inhibitor efficacy in advanced breast cancer. Sci Rep. 2024;14:9869.","journal-title":"Sci Rep"},{"key":"16548_CR17","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s10147-024-02625-w","volume":"29","author":"A Mitsuyoshi","year":"2024","unstructured":"Mitsuyoshi A, Nagahashi M, Kanaoka H, Oshiro A, Togashi Y, Hattori A, et al. Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4\/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer. Int J Clin Oncol. 2024;29:1850\u20139.","journal-title":"Int J Clin Oncol"},{"key":"16548_CR18","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38:1346\u201366.","journal-title":"J Clin Oncol"},{"key":"16548_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322.","journal-title":"J Clin Oncol"},{"key":"16548_CR20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10147-025-02768-4","volume":"30","author":"Y Togashi","year":"2025","unstructured":"Togashi Y, Nagahashi M, Oshiro A, Sugimoto G, Mitsuyoshi A, Kanaoka H, et al. Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan. Int J Clin Oncol. 2025;30:1331\u201340.","journal-title":"Int J Clin Oncol"},{"key":"16548_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","volume":"11","author":"I Valle","year":"2025","unstructured":"Valle I, Grinda T, Antonuzzo L, Pistilli B. Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives. npj Breast Cancer. 2025;11:102.","journal-title":"npj Breast Cancer"},{"key":"16548_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/bjc.2015.183","volume":"113","author":"CH Koh","year":"2015","unstructured":"Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113:150\u20138.","journal-title":"Br J Cancer"},{"key":"16548_CR23","doi-asserted-by":"publisher","first-page":"9503025","DOI":"10.1155\/2017\/9503025","volume":"2017","author":"M Zhang","year":"2017","unstructured":"Zhang M, Huang XZ, Song YX, Gao P, Sun JX, Wang ZN. High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: A meta-analysis. BioMed Res Int. 2017;2017:9503025.","journal-title":"BioMed Res Int"},{"key":"16548_CR24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/bjs\/znac319","volume":"109","author":"F Savioli","year":"2022","unstructured":"Savioli F, Morrow ES, Dolan RD, Romics L, Lannigan A, Edwards J, et al. Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. Br J Surg. 2022;109:1206\u201315.","journal-title":"Br J Surg"},{"key":"16548_CR25","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1097\/MS9.0000000000003687","volume":"87","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Inflammatory blood markers in breast cancer: a narrative review from early detection to therapy response. Ann Med Surg (Lond). 2025;87:5906\u201311.","journal-title":"Ann Med Surg (Lond)"},{"key":"16548_CR26","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395.","journal-title":"Cancer Treat Rev"},{"key":"16548_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/biomedicines12071491","volume":"12","author":"S Nucera","year":"2024","unstructured":"Nucera S, Conti C, Martorana F, Wilson B, Genta S. Antibody-drug conjugates to promote immune surveillance: lessons learned from breast cancer. Biomedicines. 2024;12:1491.","journal-title":"Biomedicines"},{"key":"16548_CR28","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"16548_CR29","doi-asserted-by":"publisher","first-page":"2533488","DOI":"10.1080\/2162402X.2025.2533488","volume":"14","author":"O Kepp","year":"2025","unstructured":"Kepp O, Kroemer G. Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates. Oncoimmunology. 2025;14:2533488.","journal-title":"Oncoimmunology"},{"key":"16548_CR30","doi-asserted-by":"publisher","first-page":"1632705","DOI":"10.3389\/fimmu.2025.1632705","volume":"16","author":"R Shi","year":"2025","unstructured":"Shi R, Jia L, Lv Z, Cui J. Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications. Front Immunol. 2025;16:1632705.","journal-title":"Front Immunol"},{"key":"16548_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346.","journal-title":"Cancer Sci"},{"key":"16548_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: Fact or fiction? Curr Oncol Rep. 2022;24:809\u201317.","journal-title":"Curr Oncol Rep"},{"key":"16548_CR33","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41598-018-37633-0","volume":"9","author":"M Imamura","year":"2019","unstructured":"Imamura M, Morimoto T, Egawa C, Fukui R, Bun A, Ozawa H, et al. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. Sci Rep. 2019;9:1811.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16548-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:38:43Z","timestamp":1791326323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16548-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16548"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16548-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the present study were conducted in accordance with the ethical standards of the ethics committee of Saitama Medical University International Medical Center\n                      (\n                      approval no.: 19\u2013224; Hidaka, Japan\n                      )\n                      and\/or the national research committee, as well as the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards. The requirement for written informed patient consent was waived, given the study\u2019s retrospective nature.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1201"}}